BNGO — Bionano Genomics, Inc.

Summary of Bionano Genomics, Inc. Q4 and Full Year 2025 Earnings Call

1. Key Financial Results and Metrics

• Q4 2025 Revenue: $8.0 million, a decrease of 3% from $8.2 million in Q4 2024, but within the preannounced range.
• Full Year 2025 Revenue: $28.5 million, down 7% from $30.8 million in 2024. Adjusted for clinical services, core revenue was down 2%.
• Flow Cell Sales: Sold 7,554 flow cells in Q4, a 6% year-over-year decline. For the full year, 30,171 flow cells were sold, down 0.4%.
• Gross Margin: Q4 non-GAAP gross margin at 43%, up from 42% YoY; full year gross margin improved to 47% from 35%.
• Operating Expenses: Q4 non-GAAP operating expenses were $9.7 million, down 9% YoY; full year expenses fell 47% to $36.6 million.
• Cash Position: Ended 2025 with $29.6 million in cash and equivalents, with a cash runway extending into 2027.

2. Strategic Updates and Business Highlights

• Strategic Shift: Since September 2024, the focus has shifted from aggressive expansion to profitable growth, targeting high-volume users and selective customer acquisition.
• Customer Base: Identified routine-use customers as key drivers of consumables revenue, accounting for 83% of OGM consumables revenue in 2025.
• Publications and Reimbursement: Achieved a record 136 new peer-reviewed publications in 2025, supporting reimbursement efforts. Established a second Category I CPT code for OGM, increasing reimbursement rates significantly.
• Product Development: Continued enhancements to VIA software and the IONIQ system, improving usability and expanding applications.

3. Forward Guidance and Outlook

• 2026 Revenue Guidance: Projected revenue of $30 million to $33 million, indicating growth of 5% to 16% over 2025.
• Q1 2026 Guidance: Expected revenue of $6.5 million to $6.7 million, representing flat to 3% growth YoY.
• Focus on Routine Users: Anticipated growth driven by existing routine-use customers and new customer acquisitions.

4. Bad News, Challenges, or Points of Concern

• Revenue Decline: Both quarterly and annual revenues declined, with a noted decrease in flow cell sales due to supply constraints.
• Customer Stability: Transitioning customer base during strategic shifts raised concerns about stability, although recent trends show some improvement.
• Supply Chain Issues: Manufacturing delays from partners affected the availability of consumables, impacting sales in Q4.

5. Notable Q&A Insights

• New OGM Systems: Management refrained from providing specific guidance on the number of new OGM systems expected to be installed in 2026, indicating flexibility in their approach.
• Flow Cell Sales Outlook: Expected consumables volume to track with revenue growth, with potential for improvement as supply constraints ease.
• Catalysts for Growth: The increase in reimbursement rates for hematologic malignancies is viewed as a significant catalyst for driving adoption and utilization of OGM.

This summary encapsulates the key aspects of Bionano Genomics' Q4 and full year 2025 earnings call, highlighting financial performance, strategic initiatives, future outlook, and challenges faced by the company.